| abstract |
The invention relates to formula (I), in which R is a hydrogen or halogen atom or an alkyl group (1 to 6 carbon atoms); X is one or more substituents selected from a hydrogen or halogen atom, an alkyl group (1 to 6 carbon atoms), halo-alkyl (1 to 6 carbon atoms), alkoxy (1 to 6 carbon atoms), halo -alkoxy (1 to 6 carbon atoms), cyano, hydroxy, or hydroxy-alkyl (1 to 6 carbon atoms); Y is a hydrogen or halogen atom or an alkyl group (1 to 6 carbon atoms); R1 is an NR2R3 or OR4 group; R2 and R3 are independently a hydrogen atom, an alkyl group (1 to 6 carbon atoms), hydroxy-alkyl (1 to 6 carbon atoms) or oxo-alkyl (1 to 6 carbon atoms), or R2 and R3 together with the nitrogen atom that supports them, they form a heterocycle optionally substituted by an alkyl group (1 to 6 carbon atoms), hydroxy, or oxo; and R4 is an alkyl (1 to 6 carbon atoms), hydroxy-alkyl (1 to 6 carbon atoms), or oxo-alkyl (1 to 6 carbon atoms) group, in the state of base addition salt or acid. The formula can be used therapeutically to treat or prevent diseases related to Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1, and HZF3. |